Pediatric
-
Mounjaro (Tirzepatide) Significantly Improves A1C in Pediatric Type 2 Diabetes: Phase 3 Trial Results.
The SURPASS-PEDS Phase 3 trial evaluated Mounjaro (tirzepatide) in pediatric patients (10-17) with type 2 diabetes. Mounjaro significantly reduced A1C and BMI compared to placebo after 30 weeks, improvements sustained through 52 weeks. 86.1% of subjects on 10mg Mounjaro achieved an A1C target ≤6.5%. The safety profile was consistent with adult studies. Lilly seeks regulatory approval to expand Mounjaro’s label for this younger population, addressing a critical unmet need given the rise of type 2 diabetes in children.
